<DOC>
	<DOC>NCT00419718</DOC>
	<brief_summary>The trial is conducted in Europe. This clinical pharmacology trial investigates the effect of exercise on the pharmacokinetics and pharmacodynamics of inhaled insulin in subjects with type 1 diabetes.</brief_summary>
	<brief_title>Effect of Exercise on the Absorption of Inhaled Human Insulin in Subjects With Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 1</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Type 1 diabetes more than or equal to 12 months Baseline HbA1c less than or equal to 11% Body mass index (BMI) less than or equal to 29 kg/m2 Normal lung volumes Treatment with intensified insulin therapy for at least 3 months Any present or history of pulmonary disease Any findings from the cardiopulmonary exercise test compromising safety of moderate exercise Impaired hepatic or renal function Cardiac problems Uncontrolled hypertension Current proliferative retinopathy or maculopathy Treatment with drugs, which may interfere with insulin action, glucose metabolism or recovery from hypoglycaemia (judged by investigator) Current smoking or smoking within the last 6 months Blood donation (more than 500 mL) within the last nine weeks</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>